Source link : https://newshealth.biz/health-news/selpercatinib-cuts-recurrence-risk-in-early-ret-nsclc/
In the first phase 3 trial of a RET inhibitor as adjuvant therapy, selpercatinib markedly improved event-free survival vs placebo in early-stage RET fusion-positive NSCLC. Medscape Medical News Source link : https://www.medscape.com/viewarticle/selpercatinib-cuts-recurrence-risk-early-ret-non-small-cell-2026a1000i25?src=rss Author : Publish date : 2026-05-31 12:20:00 Copyright for syndicated content belongs to the linked Source.
The post Selpercatinib Cuts Recurrence Risk in Early RET+ NSCLC first appeared on News Health.
—-
Author : News Health
Publish date : 2026-05-31 12:20:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8